This is a phase II multicenter, open-label study of polatuzumab vedotin administered by IV
infusion in combination with standard doses of bendamustine (B) and rituximab (R) in
transplant-eligible patients with relapsed or refractory DLBCL. A total of 22 patients will
be enrolled over a period of 2 years through the University of Colorado and additional study
sites if applicable. Study treatment will be given in 21-day cycles for patients with DLBCL.